Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"Reversing Glycation with a Dietary Supplement Containing Rosemary Extract.","authors":"Zoe Draelos, Vivian Bucay, Jacqueline Watchmaker, Giuseppe Valacchi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>The authors sought to explore the skin deglycation ability of rosemary extract dietary supplements to support skin health and improve the signs of skin aging.</p><p><strong>Methods: </strong>A PubMed literature search for English-language articles on rosemary extract effects on glycation and skin aging in clinical and/or preclinical settings was conducted.</p><p><strong>Results: </strong>Endogenous and exogenous glycative stress and reactive oxygen species lead to the accumulation of advanced glycation endproducts (AGEs), accelerating skin aging. Rosemary extract, and its active polyphenol, rosmarinic acid (RA), exhibit antiglycative and antioxidant effects, preventing AGE formation. Rosemary reduces reactive intermediates in the glycation pathway, decreases protein carbonylation, and protects against environmental stressors. Rosemary has shown potential in reversing glycation, benefiting skin health by protecting collagen and elastin. Both topical and oral delivery methods have been investigated and have shown to be beneficial. Manufacturing and extraction methods are critical in preserving essential and synergistic components of the extract when optimizing formulation development.</p><p><strong>Limitations: </strong>As a narrative review, the selection of the literature was not fully comprehensive, thus introducing a potential for bias. However, our aim was to provide insights into the impacts of glycation and RA on skin quality and health.</p><p><strong>Conclusion: </strong>Rosemary extract and RA appear to exhibit antiglycative effects, both interrupting AGE formation and AGE-protein crosslinks, making them promising compounds for skin health. However, further research is needed to fully understand their mechanisms and therapeutic potential.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 2","pages":"44-49"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin 101: Understanding the Fundamentals of Skin Barrier Physiology-Why is This Important for Clinicians?","authors":"James Q Del Rosso, Leon Kircik","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This article reviews epidermal barrier dysfunctions and more thoroughly discusses the stratum corneum (SC) permeability barrier, physiologic self-repair mechanisms in healthy skin, and the clinical and structural effects of an overstressed SC permeability barrier. Discussion includes epidermal barrier impairments induced by both exogenous exposures and endogenous factors such as specific dermatologic disorders. Due the plethora of skin care products on the market and the variability of their contents and vehicle formulations, this article addresses core concepts required to optimize skin care product selection, including for specific disease states such as atopic dermatitis, psoriasis, acne vulgaris, and rosacea. To summarize, the selection of skin care products is directed at maintaining SC hydration, including assisting the SC in self-repair when conditions are adverse. This approach optimizes the ability to sustain healthy skin structure, function and appearance.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 2","pages":"7-15"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of Complementary and Alternative Medicines in Medical Dermatology: A Comprehensive Review.","authors":"Promise Ufomadu, Bartley Joseph Gill, Ida Orengo, Theodore Rosen, Ikue Shimizu","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>In recent years, there has been a widespread patient use of complementary and alternative medicines (CAMs) for dermatological application, despite few RCT-level studies on these supplements. This creates a barrier for dermatologists and others in counseling patients who may be using or might be tempted to use these CAM agents. This review investigates various CAM modalities used by patients for medical dermatology, exploring their efficacy and toxicity profiles.</p><p><strong>Methods: </strong>A comprehensive review was performed on the effectiveness of several CAMs utilized in medical dermatology by patients. A literature search was conducted using PubMed, Embase, Google Scholar, Web of Science, and Cochrane.</p><p><strong>Results: </strong>Most CAM modalities had statistically insignificant results, and for agents that had significant results in efficacy, these studies were questionable with flawed designs and methodologies.</p><p><strong>Conclusion: </strong>These CAM supplements have promising potential in dermatologic use and are deserving of further investigation in well-crafted RCT-level studies. A more practical focus in future studies should involve a comparison of CAM agents to conventional therapies either alone or in an integrative fashion. This would accurately represent how these agents will be used clinically by actual patients and will be more helpful to clinicians. In the meantime, dermatologists should be aware of bias in published studies demonstrating the effectiveness of certain CAM modalities, and their corresponding toxicity. By doing so, physicians act as a valuable resource to patients who would like to explore various CAM products, better guiding patient interactions and treatment with improved patient outcomes.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 2","pages":"E61-E79"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sunscreen Coverage as Preventive Care Under the Affordable Care Act: A Low-Cost Way to Reduce the Prevalence of the Most Common Cancer.","authors":"Kylie A Fletcher, Eva Rawlings Parker, Brian C Drolet","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Skin cancer is the most commonly diagnosed malignancy in the United States, costing more than $8.1 billion annually in treatment-related expenses, yet with ultraviolet exposure considered the most significant risk factor for skin cancer development, cutaneous malignancy is also highly preventable. The Affordable Care Act (ACA) is committed to covering demonstrably effective preventive health care measures without patient cost sharing. To prevent skin cancer, the American Academy of Dermatology recommends applying sunscreen, donning sun-protective clothing, seeking shade, and avoiding midday sun. Additionally, The US Preventive Services Task Force recommends behavioral counseling for skin cancer prevention, including application of broad-spectrum sunscreen, from ages six months to 24 years of age. Despite these evidence-based recommendations and widespread precedent for ACA coverage of certain over-the-counter medications, dermatologic products such as sunscreen are notably excluded. Herein, we address an under-recognized insurance coverage gap for patients by outlining the evidence that sunscreen, as a primary prevention, dually reduces skin cancer incidence and healthcare costs, highlighting the critical need to address barriers to sunscreen utilization. As such, we advocate for amendment of current ACA coverage to include the cost of sunscreen as an evidence-based strategy to decrease the incidence of UV-induced cutaneous disease and associated treatment expenses.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 2","pages":"56-59"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments.","authors":"Beth Childs, Sarah Romanelli, Joseph F Merola, Alice B Gottlieb","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Psoriasis (PsO) is an immune-mediated, chronic inflammatory skin disease that significantly impairs quality of life. Its treatment landscape is rapidly evolving, providing better disease control. Here, we highlight updates in biologics, obtaining coverage for biologics under Medicare, the PsO-to-psoriatic arthritis (PsA) transition, and orally administered drugs, as presented at the 2024 Masterclass in Dermatology in Puerto Rico. We provide a concise overview of the evolving therapeutic landscape and its impact on personalized care for patients with PsO. The toolkit of biologics is expanding, with agents that target interleukin (IL)-17 and IL-23 pathways addressing symptoms across multiple disease domains. Interchangeable biosimilars reduce financial barriers to access, particularly for tumor necrosis factor (TNF) inhibitors. An IL-36 receptor antibody, spesolimab, demonstrates efficacy in generalized pustular psoriasis. Further, Medicare has expanded coverage of certain biologics, addressing challenges to treating patients of this population. PsA is an important comorbidity that can significantly reduce quality of life. Recent studies suggest that biologic therapies-including TNF inhibitors, as well as anti-IL-17, anti-IL-23, and anti-IL-12/23 agents-protect against arthritis onset in PsO patients. In addition to traditional modes of delivery, novel formulations address widespread preference for orally administered therapies. Deucravacitinib, a tyrosine kinase (TYK) 2 inhibitor, is highly selective, effective, and safe. Additionally, JNJ-77242113, an investigational IL-23 receptor antagonist, constitutes an orally administered, targeted biologic therapy. Together, these developments are shaping the future for patients with PsO. It is our goal to simplify the complexities of emerging treatment options, offering clinicians a concise and useful guide for patient management.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 2","pages":"16-22"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Skin Deep: The Systemic Impact of Topical Corticosteroids in Dermatology.","authors":"Douglas DiRuggiero, Margaret DiRuggiero","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Corticosteroids are widely prescribed for a variety of dermatologic indications. However, since 2020, regulatory bodies from Canada and the United Kingdom, as well as academic and patient advocacy societies, are increasingly calling for limiting topical corticosteroid use due to safety concerns. This article reviews the variety and extent of both cutaneous adverse effects (i.e., steroid-induced damage) and systemic adverse effects from topical corticosteroids and explores alternative therapies. The risk of adverse effects increases with steroid potency, amount, duration, and frequency of use across indications, routes of administration, and prescribers (i.e., cumulative steroid dose). In order to reduce these safety risks, clinicians should prescribe steroids appropriately and counsel patients on appropriate use and consider combination topical corticosteroid therapy or newer alternative steroid-sparing treatments.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 1-2 Suppl 1","pages":"S16-S20"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11903052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Videoconferencing Dysmorphia: The Impact on Self-perception and Desire for Cosmetic Procedures.","authors":"Payal M Patel, Mindy D Szeto, Kelly O'Connor, Henriette De La Garza, Kevin F Kennedy, Mayra B C Maymone, Neelam A Vashi","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;The authors sought to examine the association between the increased use of videoconferencing and image-enhancing software filters during the COVID-19 pandemic and the corresponding rise in interest in cosmetic procedures. We aimed to discern if heightened exposure to one's digital self-image correlates with a greater inclination toward cosmetic interventions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this cross-sectional questionnaire survey study, adult participants living in the United States were recruited on Amazon's Mechanical Turk platform. Self-reported demographic data, videoconferencing usage, related behaviors, and attitudes concerning cosmetic procedures were assessed. Questionnaire prompts allowed participants to express in a Likert scale format their levels of agreement with certain statements. Frequencies and proportions of responses to each questionnaire item were collected, categorized, and recoded for comparison and analysis. Chi-squared tests were performed to examine associations between questionnaire responses and demographic characteristics, while significant predictors of videoconferencing and image-enhancing filter options were explored via multivariable logistic regression models.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The majority of study participants (n=505, 505/545 = 92.7% completion rate) were 18 to 39 years old (80.1%), female (68.1%), and non-White (58.2%). Income levels varied, and 89.2 percent had completed college or graduate school. Videoconferencing was frequent, with 88.6 percent using it more than three days a week, and 68.1 percent using \";touch-up my appearance\"; filters more than half the time. Videoconferencing influenced the desire for cosmetic procedures in 55.9 percent of participants, and 57.8 percent were influenced by filter use. Frequent self-viewing was reported by 67 percent, strongly associated with interest in cosmetic procedures. Significant predictors of filter use included higher income (OR 2.436, &lt;i&gt;p&lt;/i&gt;&lt;0.001) and frequent self-viewing behavior (OR 5.034, &lt;i&gt;p&lt;/i&gt;&lt;0.001). Notably, mask-wearing was associated with increased self-esteem (68.8%) and reduced desire for cosmetic procedures (67.4%) in frequent self-viewers.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations: &lt;/strong&gt;Recall bias and the demographic composition of the study participant population may limit the generalizability of these self-reported responses.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The data reflect the emergence of what may be termed 'videoconferencing dysmorphia,' indicating a significant association between videoconferencing, the application of filters, and the heightened interest in cosmetic procedures among users. This study suggests that digital self-viewing behavior instigates a distinct self-awareness that may drive individuals toward considering cosmetic interventions. These insights are vital for dermatologists in understanding patient motivations, managing expectations, and fostering realistic treatment outcomes.&lt;","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 1","pages":"46-51"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11741173/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143016484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Botulinum Toxin-loaded Detachable Dissolvable Microneedles for Primary Axillary Hyperhidrosis: A Pilot Study on Efficacy and Safety.","authors":"Jidapa Triwatcharikorn, Kridipop Charoenchaipiyakul, Titiporn Sansureerungsikul, Nunthanach Chuenboonngarm, Kornphaka Kantikosum, Natcha Chottawornsak, Bussabong Chancheewa, Thanaporn Puaratanaarunkon, Ratchathorn Panchaprateep, Chanat Kumtornrut, Puttikorn Pukfukdee, Supason Wanichwecharungruang, Pravit Asawanonda","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Botulinum toxin injection is a well-established treatment for primary hyperhidrosis. The botulinum toxin-loaded detachable dissolvable microneedles (BoNT-MNs) were developed in a result of disadvantages of the intradermal procedure. This pilot study aims to evaluate the efficacy and safety of BoNT-MNs.</p><p><strong>Methods: </strong>This within-subject study included ten adults (N=10; 100% female) with mild primary axillary hyperhidrosis. BoNT-MNs patches were prepared and each microneedle patch contained 15 units of onabotulinum toxin. BoNT-MNs and placebo patches were randomly applied to different sides of axilla. Iodine-starch test, dermatologists' and patients' satisfaction scores were assessed at baseline and Weeks 1, 2, 3, 4, 8, 12, 16, 20, and 24.</p><p><strong>Results: </strong>All ten female subjects completed the trial. Notably, on the BoNT-MNs side, iodine starch scores exhibited an onset at Week 2, with a 57.14-percent reduction at Week 12, returning to baseline after Week 20. Dermatologists' and patients' satisfaction scores were consistently superior to the placebo side from Week 2 and Week 1, respectively, until Week 16, with statistical significance (<i>p</i><0.05) observed at Week 12 and Week 2.</p><p><strong>Limitations: </strong>This study involved a limited number of female participants and administered a single, small dosage of botulinum toxin in the BoNT-MNs.</p><p><strong>Conclusions: </strong>Botulinum toxin-loaded detachable dissolvable microneedles patches offer a safe and effective method for reducing axillary sweating.</p><p><strong>Clinical trial: </strong>This study was approved by the Institutional Review Board of Faculty of Medicine, Chulalongkorn University with IRB number 567/63, and registered in the Thai Clinical Trials Registry (Thaiclinicaltrials.org) under registration number TCTR20201230002.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 1","pages":"E61-E66"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11741174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143016405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of Internet and Social Media by Outpatient Dermatology Patients: A Prospective, Cross-sectional Study.","authors":"Autumn L Saizan, Simone N Montgomery, Li Ding, Arielle Carolina Mora Hurtado, Nada Elbuluk","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Online health-related information (HRI) has expanded access to medical knowledge. While there are benefits to the increasing availability of online HRI, there may be limitations to the accuracy, quality of information, and utilization across patient demographics.</p><p><strong>Methods: </strong>A survey was administered to dermatology outpatients at the Keck School of Medicine of the University of Southern California to examine the utilization of internet and social media for acquiring dermatology-related information (DRI).</p><p><strong>Results: </strong>A total of 200 patients completed the survey. A majority (90%) indicated utilizing the internet to research information about their dermatological condition. Approximately 74 percent researched their dermatological condition before visiting the dermatologist, and 80 percent researched their condition after seeing a dermatologist. Younger patients (ages 18-25) were more likely to utilize online HRI before and after their visit. When stratified by income level, those with an income of less than $20,000 a year were more likely to search online for symptom management. Overwhelmingly, patients (99%) preferred to receive DRI from a dermatologist over internet or social media.</p><p><strong>Limitations: </strong>A limitation of our study is the exclusion of individuals with dermatologic issues who do not seek in-person dermatologic care, which may contribute to selection bias.</p><p><strong>Conclusion: </strong>There are differences across demographics in the utilization of the internet and social media for obtaining DRI. Understanding patients' interactions with online HRI may allow providers and patients to work synergistically, leveraging online resources to support the dissemination of credible information and optimize patient outcomes.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 1","pages":"29-34"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11741166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143016481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recalcitrant Pediatric Facial Vitiligo Successfully Treated with Roflumilast Cream 0.3% Once Daily.","authors":"Kelly Warren, Sofia Sanchez","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Vitiligo is an autoimmune disorder that causes melanocyte damage and pigment loss. The clinical presentation of vitiligo consists of patchy areas of lighter skin and results from a loss of functioning melanocytes and may be more visible in darker skin toned patients. Vitiligo affects approximately 2 percent of children and adolescents in the United States, with half of the affected cases undiagnosed. Pediatric patients are at a high risk of experiencing psychosocial adverse events such as depression and anxiety if the vitiligo is not quickly or effectively treated due primarily to the visual presentation of the disease. These adverse events may be seen especially in patients with a darker skin tone. Treatments for pediatric vitiligo in the past has usually included phototherapy, topical corticosteroids, vitamin D and calcineurin inhibitors; topical ruxolitinib has been approved more recently for nonsegmental vitiligo in patients 12 years of age and older. In cases where disease is recalcitrant, the need for additional therapies is warranted. Roflumilast cream 0.3% is a highly selective, non-steroidal and potent topical phosphodiesterase 4 inhibitor approved in 2022 by the United States Food and Drug Administration for the treatment of psoriasis, in 2023 as a foam for the treatment of seborrheic dermatitis and in 2024, roflumilast cream 0.15% was approved for the treatment of atopic dermatitis, including in children down to six years of age. Topical roflumilast is well tolerated with a favorable safety profile among pediatric dermatology populations. We describe four cases of pediatric skin of color patients with facial vitiligo that were refractory to topical corticosteroids, ruxolitinib and phototherapy. All patients were started on roflumilast cream 0.3% once daily and demonstrated improvement in repigmentation.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 1","pages":"52-54"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11741172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143016440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}